Nov 08, 2022 / 10:00PM GMT
Judah Frommer - Credit Suisse - Analyst
Good afternoon, everyone. I'm Judah Frommer. I'm one of the SMID-cap biotech analysts here at Credit Suisse. And for this session, we're very happy to have the team from eFFECTOR here: Steve, Mike, and Doug.
So maybe if we just jump right in. We thought we could start with a background question on the platform and the origin story for -- how did you land on the eIF4F translation complex? And how should we think about the optionality available for potential therapeutic mechanisms?
Questions and Answers:
Steve Worland - eFFECTOR Therapeutics, Inc. - President & CEOYeah. Thanks, Judah. Thanks for the invitation. It's great to be here. I mean, I'll start with that. And then -- a lot of other people join in.
So I think the idea with the translational complex was, one, recognizing where it sits in cell signaling. So it's downstream of the RAS and the PI3K pathways, and it's actually a point of convergence of those two pathways, one of the very early points in signaling where the two pathways
Trustpilot
